In vivo and in vitro characterization of basal insulin peglispro: A novel insulin analogs

Journal of Pharmacology and Experimental Therapeutics

Volumn 357, Issue 3, 2016, Pages 459-465

  Owens, Rebecca A ^a   Hansen, Ryan J ^a   Kahl, Steven D ^a   Zhang, Chen ^a   Ruan, Xiaoping ^a   Koester, Anja ^a   Li, Shun ^a   Qian, Hui Rong ^a   Farmen, Mark W ^a   Michael, M Dodson ^a   Moyers, Julie S ^a   Cutler, Gordon B ^a,b   Vick, Andrew ^a,c   Beals, John M ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Gordon Cutler Consultancy   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN PEGLISPRO; INSULIN RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; MACROGOL DERIVATIVE; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG POTENCY; EMBRYO; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; 3T3-L1 CELL LINE; ADIPOCYTE; ANIMAL; CELL DIFFERENTIATION; CHEMISTRY; CYTOLOGY; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; ENZYME SPECIFICITY; LIPOGENESIS; MALE; METABOLISM; MOUSE; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; DIABETES MELLITUS, EXPERIMENTAL; HUMANS; INSULIN LISPRO; LIPOGENESIS; MALE; MICE; PHOSPHORYLATION; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SUBSTRATE SPECIFICITY; TYROSINE;

EID: 84974624926     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.231035     Document Type: Article

References (45)

1. American Type Culture Collection (2011) Chemically-induced differentiation of ATCC® CL-173™ (3T3-L1) using single-component commercially-available reagents, American Type Culture Collection, Manassas, VA.
2. Bergenstal RM, Rosenstock J, Arakaki RF, Prince MJ, Qu Y, Sinha VP, Howey DC, and Jacober SJ (2012) A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 35:2140-2147.
3. Bergenstal RM, Rosenstock J, Bastyr EJ, 3rd, Prince MJ, Qu Y, and Jacober SJ (2014) Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine. Diabetes Care 37:659-665.
4. Bolli GB, Andreoli AM, and Lucidi P (2011) Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther 13 (Suppl 1):S43-S52.
5. Brunner GA, Sendhofer G, Wutte A, Ellmerer M, Søgaard B, Siebenhofer A, Hirschberger S, Krejs GJ, and Pieber TR (2000) Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes 108:100-105.
6. Charman SA, McLennan DN, Edwards GA, and Porter CJ (2001) Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model. Pharm Res 18:1620-1626.
7. Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, and DeFronzo RA (1983) Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol 244:E517-E527.
8. Flier JS, Minaker KL, Landsberg L, Young JB, Pallotta J, and Rowe JW (1982) Impaired in vivo insulin clearance in patients with severe target-cell resistance to insulin. Diabetes 31:132-135.
9. Hagedorn HC, Jensen BN, Krarup NB, and Wodstrup I (1984) Landmark article Jan 18, 1936: Protamine insulinate. By H.C. Hagedorn, B.N. Jensen, N.B. Krarup, and I. Wodstrup. JAMA 251:389-392.
10. Hallas-Moller K (1956) The lente insulins. Diabetes 5:7-14.
11. Hansen BF, Danielsen GM, Drejer K, Sørensen AR, Wiberg FC, Klein HH, and Lundemose AG (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271-279.
12. Hansen BF, Glendorf T, Hegelund AC, Lundby A, Lützen A, Slaaby R, and Stidsen CE (2012a) Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10. PLoS One 7:e34274.
13. Hansen BF, Kurtzhals P, Jensen AB, Dejgaard A, and Russell-Jones D (2011) Insulin X10 revisited: a super-mitogenic insulin analogue. Diabetologia 54:2226-2231.
14. Hansen RJ, Cutler GB, Jr, Vick A, Koester A, Li S, Siesky AM, and Beals JM (2012b) P-896: LY2605541: Leveraging hydrodynamic size to develop a novel basal insulin. Diabetes Care 61:A228.
15. Havelund S, Plum A, Ribel U, Jonassen I, Vølund A, Markussen J, and Kurtzhals P (2004) The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 21:1498-1504.
16. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, and Haahr H (2012) Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 14:859-864.
17. Heise T, Hövelmann U, Nosek L, Bøttcher S, Granhall C, and Haahr H (2011) Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes Care 60 (Suppl 1A):LB11.
18. Henriksen JH, Tronier B, and Bülow JB (1987) Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man. Metabolism 36:463-468.
19. Henry RR, Mudaliar S, Ciaraldi TP, Armstrong DA, Burke P, Pettus J, Garhyan P, Choi SL, Jacober SJ, and Knadler MP, et al. (2014) Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care 37(9, Suppl 1)2609-2615.
20. Herring R, Jones RH, and Russell-Jones DL (2014) Hepatoselectivity and the evolution of insulin. Diabetes Obes Metab 16:1-8.
21. Hodges RS, Heaton RJ, Parker JM, Molday L, and Molday RS (1988) Antigen-antibody interaction. Synthetic peptides define linear antigenic determinants recognized by monoclonal antibodies directed to the cytoplasmic carboxyl terminus of rhodopsin. J Biol Chem 263:11768-11775.
22. Hordern SV, Wright JE, Umpleby AM, Shojaee-Moradie F, Amiss J, and Russell-Jones DL (2005) Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 48:420-426.
23. Jacober SJ, Rosenstock J, Bergenstal RM, Prince MJ, Qu Y, and Beals JM (2014) Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. Diabetes Obes Metab 16:351-356.
24. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, and Ribel U (2012) Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 29:2104-2114.
25. Jorgensen LN, Dideriksen LH, and Drejer K (1992) Carcinogenic effect of the insulin analogue B10 Asp on female rats. Diabetologia 35:A3.
26. Kohn WD, Micanovic R, Myers SL, Vick AM, Kahl SD, Zhang L, Strifler BA, Li S, Shang J, and Beals JM, et al. (2007) pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity. Peptides 28:935-948.
27. Krayenbühl CR and Rosenberg T (1946) Crystalline protamine insulin. Rep Steno Memorial Hosp 1:60-73.
28. Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, and Trüb T (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005.
29. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, and Bolli GB (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142-2148.
30. Liefvendahl E and Arnqvist HJ (2008) Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 40:369-374.
31. Logtenberg SJ, Kleefstra N, Houweling ST, Groenier KH, Gans RO, van Ballegooie E, and Bilo HJ (2009) Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial. Diabetes Care 32:1372-1377.
32. Moore MC, Smith MS, Sinha VP, Beals JM, Michael MD, Jacober SJ, and Cherrington AD (2014) Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 63:494-504.
33. Nishimura E, Sørensen A, Hansen B, Stidsen C, Olsen G, Schäffer L, Bonnesen C, Hegelund A, Lundby A, and Jonassen I (2010) Insulin degludec is a new generation ultra-long acting basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential. Diabetes Care 59:A1406.
34. Novo Nordisk (2013) Levemir (insulin detemir [rDNA origin] injection) prescribing information, Novo-Nordisk, Plainsboro, NJ.
35. Oprian DD, Molday RS, Kaufman RJ, and Khorana HG (1987) Expression of a synthetic bovine rhodopsin gene in monkey kidney cells. Proc Natl Acad Sci USA 84:8874-8878.
36. Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, Owens DR, Bolli GB, and Fanelli CG (2007) Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 30:2447-2452.
37. Rabkin R, Simon NM, Steiner S, and Colwell JA (1970) Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med 282:182-187.
38. Rosenstock J, Bergenstal RM, Blevins TC, Morrow LA, Prince MJ, Qu Y, Sinha VP, Howey DC, and Jacober SJ (2013) Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care 36:522-528.
39. Sanofi-Aventis (2013) Lantus (insulin glargine [rDNA origin] injection) prescribing information, Sanofi-Aventis, Bridgewater, NJ.
40. Sinha VP, Choi SL, Soon DK, Mace KF, Yeo KP, Lim ST, and Howey DC (2014a) Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J Clin Pharmacol 54:792-799.
41. Sinha VP, Howey DC, Choi SL, Mace KF, and Heise T (2014b) Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab 16:344-350.
42. Sørensen AR, Stidsen CE, Ribel U, Nishimura E, Sturis J, Jonassen I, Bouman SD, Kurtzhals P, and Brand CL (2010) Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. Diabetes Obes Metab 12:665-673.
43. Vora J and Heise T (2013) Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review. Diabetes Obes Metab 15:701-712.
44. Waldhäusl W, Bratusch-Marrain P, Gasic S, Korn A, and Nowotny P (1979) Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man. Diabetologia 17:221-227.
45. Wang F, Carabino JM, and Vergara CM (2003) Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 25:1541-1577, discussion 1539-1540.